Minimal-change glomerulopathy and glomerular visceral epithelial hyperplasia associated with alpha-interferon therapy

A Traynor1, T Kuzel, E Samuelson

  • 1Department of Medicine, Northwestern University Medical School, Chicago, IL 60611.

Nephron
|January 1, 1994
PubMed

Insights

A patient with T-cell lymphoma developed kidney failure after interferon treatment, showing podocyte damage. Treatment with prednisone improved kidney function, suggesting lymphokine-mediated nephrotoxicity.

Area of Science:

  • Nephrology
  • Oncology
  • Immunology

Background:

  • Cutaneous T-cell lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma.
  • Alpha-interferon is a common treatment for CTCL, but can have side effects.

Observation:

  • A 44-year-old man with CTCL experienced complete skin regression after alpha-interferon therapy.
  • Concurrently, he developed acute renal failure, characterized by nephrotic-range proteinuria, interstitial nephritis, and minimal-change nephropathy.

Findings:

  • Renal biopsy revealed significant proliferation of visceral epithelial cells (podocytes).
  • Discontinuation of alpha-interferon and initiation of prednisone therapy led to significant improvement in renal function and proteinuria.

Implications:

  • This case highlights a potential link between lymphoproliferative disorders and interferon-induced nephrotoxicity.
  • Podocyte injury may play a crucial role in the pathogenesis of this condition.
  • Further research is warranted to understand lymphokine-mediated effects on renal function in lymphoma patients.